David Johnson Einstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 14 | 2024 | 11118 | 1.420 |
Why?
|
Carcinoma, Renal Cell | 6 | 2024 | 3163 | 0.900 |
Why?
|
Kidney Neoplasms | 5 | 2024 | 4248 | 0.860 |
Why?
|
Androgen Receptor Antagonists | 2 | 2024 | 125 | 0.820 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1090 | 0.740 |
Why?
|
Terminal Care | 5 | 2017 | 1760 | 0.690 |
Why?
|
Urogenital Neoplasms | 1 | 2020 | 131 | 0.660 |
Why?
|
Receptors, Androgen | 3 | 2023 | 1079 | 0.650 |
Why?
|
Phenylurea Compounds | 1 | 2022 | 529 | 0.640 |
Why?
|
Androstenes | 2 | 2019 | 181 | 0.640 |
Why?
|
Compassionate Use Trials | 1 | 2018 | 50 | 0.620 |
Why?
|
Androgen Antagonists | 3 | 2024 | 1410 | 0.620 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9277 | 0.610 |
Why?
|
Quinolines | 1 | 2022 | 764 | 0.550 |
Why?
|
Paternalism | 1 | 2016 | 47 | 0.540 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3874 | 0.520 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2021 | 782 | 0.510 |
Why?
|
Death | 2 | 2017 | 676 | 0.510 |
Why?
|
Telephone | 1 | 2019 | 627 | 0.500 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1469 | 0.470 |
Why?
|
Advance Directives | 1 | 2016 | 249 | 0.460 |
Why?
|
Empathy | 1 | 2018 | 473 | 0.450 |
Why?
|
Physician-Patient Relations | 5 | 2022 | 3249 | 0.450 |
Why?
|
Personal Autonomy | 1 | 2016 | 304 | 0.440 |
Why?
|
Cisplatin | 1 | 2019 | 1650 | 0.410 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4575 | 0.400 |
Why?
|
Facial Paralysis | 1 | 2015 | 345 | 0.370 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3490 | 0.360 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2021 | 2223 | 0.340 |
Why?
|
Sarcoidosis | 1 | 2015 | 521 | 0.340 |
Why?
|
Quality of Life | 2 | 2023 | 13361 | 0.330 |
Why?
|
Immunotherapy | 4 | 2021 | 4650 | 0.310 |
Why?
|
Internal Medicine | 1 | 2015 | 1051 | 0.300 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2015 | 992 | 0.280 |
Why?
|
Prostate-Specific Antigen | 4 | 2024 | 2469 | 0.280 |
Why?
|
Neoplasms | 6 | 2022 | 22164 | 0.280 |
Why?
|
Prostatectomy | 4 | 2024 | 1824 | 0.280 |
Why?
|
Internet | 1 | 2019 | 3092 | 0.270 |
Why?
|
Palliative Care | 2 | 2021 | 3600 | 0.260 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5305 | 0.250 |
Why?
|
Medical Oncology | 1 | 2017 | 2321 | 0.250 |
Why?
|
Decision Making | 2 | 2016 | 3929 | 0.240 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3602 | 0.220 |
Why?
|
Leuprolide | 2 | 2024 | 312 | 0.210 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13637 | 0.210 |
Why?
|
Chromosomes, Human, X | 1 | 2024 | 321 | 0.200 |
Why?
|
Radium | 1 | 2023 | 72 | 0.200 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2022 | 43 | 0.200 |
Why?
|
Humans | 39 | 2024 | 761423 | 0.200 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2024 | 318 | 0.200 |
Why?
|
Male | 24 | 2024 | 360736 | 0.190 |
Why?
|
Thiohydantoins | 1 | 2021 | 19 | 0.190 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3889 | 0.190 |
Why?
|
Phenylthiohydantoin | 2 | 2019 | 205 | 0.180 |
Why?
|
Prednisone | 2 | 2024 | 1562 | 0.170 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 664 | 0.160 |
Why?
|
Translocation, Genetic | 1 | 2024 | 1393 | 0.160 |
Why?
|
Cryosurgery | 1 | 2023 | 474 | 0.150 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 299 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 884 | 0.140 |
Why?
|
Morbidity | 1 | 2023 | 1750 | 0.140 |
Why?
|
Nitriles | 2 | 2019 | 971 | 0.140 |
Why?
|
Forkhead Transcription Factors | 1 | 2024 | 1613 | 0.140 |
Why?
|
Urothelium | 1 | 2019 | 269 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 1 | 2021 | 1062 | 0.140 |
Why?
|
Benzamides | 2 | 2019 | 1370 | 0.140 |
Why?
|
Disease-Free Survival | 2 | 2024 | 6814 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2024 | 2455 | 0.130 |
Why?
|
Erythema Nodosum | 1 | 2015 | 31 | 0.130 |
Why?
|
Drug Approval | 1 | 2022 | 814 | 0.120 |
Why?
|
Internship and Residency | 1 | 2015 | 5879 | 0.120 |
Why?
|
Serine | 1 | 2018 | 830 | 0.120 |
Why?
|
Soft Tissue Neoplasms | 1 | 2023 | 1159 | 0.110 |
Why?
|
Phylogeny | 1 | 2021 | 2811 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2019 | 809 | 0.110 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3447 | 0.110 |
Why?
|
Anecdotes as Topic | 1 | 2012 | 56 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1520 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2047 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4510 | 0.100 |
Why?
|
Sarcoma | 1 | 2023 | 1801 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 934 | 0.090 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3589 | 0.090 |
Why?
|
Professional-Patient Relations | 1 | 2016 | 726 | 0.090 |
Why?
|
Hospice Care | 1 | 2017 | 678 | 0.090 |
Why?
|
Survival Analysis | 2 | 2020 | 10089 | 0.080 |
Why?
|
Biopsy | 1 | 2021 | 6766 | 0.080 |
Why?
|
Prognosis | 3 | 2020 | 29620 | 0.080 |
Why?
|
Virus Diseases | 1 | 2015 | 719 | 0.080 |
Why?
|
Culture | 1 | 2012 | 623 | 0.080 |
Why?
|
Aged | 7 | 2024 | 169235 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2811 | 0.070 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6485 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8545 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10203 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13502 | 0.070 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2644 | 0.070 |
Why?
|
Risk Assessment | 4 | 2021 | 23990 | 0.070 |
Why?
|
Androgens | 2 | 2024 | 1286 | 0.060 |
Why?
|
Prevalence | 1 | 2023 | 15717 | 0.060 |
Why?
|
Melanoma | 1 | 2024 | 5709 | 0.060 |
Why?
|
Middle Aged | 6 | 2024 | 220826 | 0.060 |
Why?
|
Pteridines | 1 | 2024 | 47 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26112 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11106 | 0.060 |
Why?
|
Phenotype | 1 | 2021 | 16606 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8000 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14599 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11740 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18400 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7049 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2022 | 169 | 0.050 |
Why?
|
United States | 2 | 2022 | 72339 | 0.050 |
Why?
|
Female | 5 | 2024 | 392581 | 0.050 |
Why?
|
Drug Synergism | 1 | 2024 | 1755 | 0.040 |
Why?
|
Role | 1 | 2020 | 176 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12970 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 294 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2024 | 64651 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8529 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 552 | 0.040 |
Why?
|
Haplotypes | 1 | 2024 | 2775 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2018 | 364 | 0.040 |
Why?
|
Prospective Studies | 2 | 2021 | 54415 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4591 | 0.040 |
Why?
|
Mitosis | 1 | 2023 | 1187 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 705 | 0.040 |
Why?
|
beta Catenin | 1 | 2022 | 1040 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2023 | 1264 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1606 | 0.030 |
Why?
|
Cohort Studies | 1 | 2019 | 41446 | 0.030 |
Why?
|
Mutation | 1 | 2020 | 30045 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 736 | 0.030 |
Why?
|
Animals | 4 | 2024 | 168441 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 16979 | 0.030 |
Why?
|
Perception | 1 | 2021 | 1197 | 0.030 |
Why?
|
Signal Transduction | 1 | 2017 | 23441 | 0.030 |
Why?
|
Piperazines | 1 | 2024 | 2523 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2024 | 2637 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2626 | 0.030 |
Why?
|
Testosterone | 1 | 2024 | 2472 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5246 | 0.030 |
Why?
|
Prostate | 1 | 2020 | 1770 | 0.030 |
Why?
|
Pyrimidines | 1 | 2024 | 3027 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1588 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6309 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2826 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2020 | 1852 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20556 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10441 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4244 | 0.020 |
Why?
|
Apoptosis | 1 | 2024 | 9488 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5665 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8320 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81509 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11073 | 0.010 |
Why?
|
Genomics | 1 | 2020 | 5820 | 0.010 |
Why?
|
Adult | 1 | 2015 | 221148 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39117 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 80582 | 0.010 |
Why?
|